RetiSpec Announces Partnership With Gentex To Commercialize Alzheimer’s Disease Detection Technology
RetiSpec Announces Partnership With Gentex To Commercialize Alzheimer’s Disease Detection Technology
TORONTO, Oct. 5, 2020 – RetiSpec Inc. announced today that it is partnering with Gentex Corporation (NASDAQ: GNTX) to engineer, manufacture and commercialize technology for the early detection of Alzheimer’s disease.
“The Gentex-RetiSpec partnership reinforces our commitment to bring to market RetiSpec’s novel retinal imaging technology, a widely scalable and affordable way to accurately detect Alzheimer’s Disease at both the symptomatic and pre-symptomatic stages,” said Eliav Shaked, CEO of RetiSpec. “We are excited about the prospect of partnering with Gentex and leveraging its vast expertise and innovative technologies in machine vision, imaging and electronics manufacturing.”
